SCHEMBL2214591

SCHEMBL2214591

CCOC(=O)c1cc2c3ccccc3n(Cc3ccccc3)c2c(C)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.50
KDM4E B2RXH2 4/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
CNR2 P34972 1/20 0.50
PKM P14618 1/20 0.50
TP53 P04637 1/20 0.49
TSHR P16473 4/20 0.48
NOD2 Q9HC29 1/20 0.47
NOD1 Q9Y239 1/20 0.47
ALDH1A1 P00352 5/20 0.47
HSD17B10 Q99714 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
POLB P06746 2/20 0.47
ATM Q13315 2/20 0.47
HPGD P15428 2/20 0.47
ALOX15 P16050 1/20 0.47
F2RL3 Q96RI0 1/20 0.46
TDP1 Q9NUW8 2/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28374659 0.92 KMT2A (0.53) MAPTLMNACNR2TP53ALDH1A1
SCHEMBL27910551 0.90 CNR2 (0.50) GAAKDM4EMAPTLMNACNR2
SCHEMBL2214355 0.89 KDM4E (0.56) GAAKDM4ECNR2TSHRALDH1A1
SCHEMBL2216447 0.87 CNR2 (0.49) GAAKDM4EMAPTLMNACNR2
SCHEMBL2214758 0.87 CNR2 (0.54) GAAKDM4EMAPTLMNACNR2
SCHEMBL2215283 0.87 CYP19A1 (0.49) GAAKDM4EMAPTTSHRALDH1A1
SCHEMBL2214397 0.86 CNR2 (0.48) GAAKDM4EMAPTCNR2TSHR
SCHEMBL2214585 0.85 KMT2A (0.56) GAAKDM4ELMNACNR2TP53
SCHEMBL28379309 0.85 F2RL3 (0.50) GAAKDM4EMAPTLMNACNR2
SCHEMBL4172231 0.84 CNR2 (0.64) GAAKDM4ELMNACNR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634881-B1 HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) 2011-07-27 EP claimed
US-20090227619-A1 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) 2009-09-10 US claimed
US-8772311-B2 Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) 2014-07-08 US disclosed
EP-1634881-B1 HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) 2011-07-27 EP disclosed
US-20090227619-A1 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) 2009-09-10 US disclosed
EP-1634881-A1 HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) 2006-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227619-A1 Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo TPH1, HTR1F, TPH2 GAA 1706/4885KDM4E 2869/4885MAPT 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.